Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.

por Eike Gallmeier, Dominik C Bader, Lydia Kriegl, Sabina Berezowska, Hendrik Seeliger, Burkhard Göke, Thomas Kirchner, Christiane Bruns, Enrico N De Toni
Publicado 2013

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined wit...

por Florian Gebauer, Alexander Ioannis Damanakis, Felix Popp, Alexander Quaas, Fabian Kütting, Katrin Lutz, Swantje Held, Burkhard Deuß, Tobias Göser, Dirk Waldschmidt, Christiane Bruns
Publicado 2021